Last reviewed · How we verify
Famitinib Malate Capsules
At a glance
| Generic name | Famitinib Malate Capsules |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of SHR-1802 in Patients With Advanced Solid Tumor (PHASE2)
- A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC (PHASE3)
- Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects (PHASE1)
- Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition (PHASE1)
- A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients (PHASE2)
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors (PHASE2)
- A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Famitinib Malate Capsules CI brief — competitive landscape report
- Famitinib Malate Capsules updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI